CYTK Company Profile and Key Details

Q: Who are the executives of CYTK?

Mr. Jeff LotzVice President of Sales & OperationsMr. Scott R. JordanSenior Vice President of Global Marketing & Commercial StrategyDr. Fady Ibraham Malik FACC, M.D., Ph.D.Executive Vice President of R&DDr. James A. Spudich Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Robert C. WongVice President & Chief Accounting OfficerMr. Robert I. BlumChief Executive Officer, Pres & DirectorMr. Ching W. JawSenior Vice President & Chief Financial OfficerMr. Andrew M. CallosExecutive Vice President & Chief Commercial OfficerMs. Kari K. Loeser J.D.Vice President & Chief Compliance OfficerMs. Joanna SiegallAssociate Director of Corporation Communications & Investor RelationsMr. Steven M. CookSenior Vice President of Supply Chain Operations & Technical OperationsMs. Diane WeiserSenior Vice President of Corporation Communications & Investor Relations

NASDAQ : CYTK

Cytokinetics

$61.43

-0.79-1.27%

At Close 4:00 PM

59.53

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Cytokinetics, Incorporated (CYTK) stock declined over -1.27%, trading at $61.43 on NASDAQ, down from the previous close of $62.22. The stock opened at $61.62, fluctuating between $60.45 and $62.54 in the recent session.

Stock Snapshot

62.22

Prev. Close

7.51B

Market Cap

60.45

Day Low

-9.75

P/E Ratio

-6.3

EPS (TTM)

-4.2

Cash Flow per Share

61.62

Open

122.26M

Number of Shares

62.535

Day High

99.54%

Free Float in %

-3.9

Book Value

1.45M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 02, 2026	61.62	62.54	60.45	61.43	1.46M
Feb 27, 2026	62.08	62.99	61.91	62.22	1.43M
Feb 26, 2026	62.61	63.00	60.87	62.63	2M
Feb 25, 2026	68.12	69.28	62.00	62.89	5.04M
Feb 24, 2026	68.44	70.39	67.02	70.10	1.94M
Feb 23, 2026	67.85	68.92	67.52	68.26	1.49M
Feb 20, 2026	67.72	69.12	67.45	67.94	2.02M
Feb 19, 2026	66.61	67.86	65.54	67.83	1.26M
Feb 18, 2026	66.31	67.67	66.01	66.98	1.57M
Feb 17, 2026	65.98	66.98	65.52	66.62	1.13M
Feb 13, 2026	65.49	67.54	64.58	66.26	2.08M
Feb 12, 2026	67.00	67.89	64.64	65.04	1.73M
Feb 11, 2026	65.25	66.98	63.53	66.80	1.95M
Feb 10, 2026	63.96	65.49	63.13	64.85	2.43M
Feb 09, 2026	62.21	63.68	61.58	63.36	1.07M
Feb 06, 2026	61.31	62.74	61.00	62.34	1.73M
Feb 05, 2026	63.26	64.51	60.05	60.24	1.88M
Feb 04, 2026	64.97	65.25	62.35	63.52	1.6M
Feb 03, 2026	65.86	67.10	63.64	64.73	1.43M
Feb 02, 2026	62.10	65.63	62.05	65.16	1.35M

Contact Details

South San Francisco, CA 94080

United States

https://www.cytokinetics.com 650 624 3000

About Company

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Stock Peers

REGN

9.14+1.17%

Regeneron Pharmaceuticals, Inc.$790.81 ARGX

-10.16-1.32%

argenx SE$756.76 UTHR

9.92+1.97%

United Therapeutics Corporation$513.82 VRTX

-10.8-2.17%

Vertex Pharmaceuticals Incorporated$486.03 MDGL

3.62+0.84%

Madrigal Pharmaceuticals, Inc.$435.62 PRAX

-6.16-1.83%

Praxis Precision Medicines, Inc.$330.59 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-7.85-2.36%

Alnylam Pharmaceuticals, Inc.$325.07 KRYS

-16.83-6.11%

Krystal Biotech, Inc.$258.81 ASND

8.59+3.68%

Ascendis Pharma A/S$242.09

Company Overview

Cytokinetics, Incorporated (NASDAQ:CYTK) closed at $61.43 USD, losing -$0.79 (-1.27%) from the previous close of $62.22. The stock is currently mid-range between its 52-week high and low $29.31 and $70.98. With a market capitalization of about $7.51 billion, Cytokinetics, Incorporated is classified as a mid-cap and shows lower-than-market volatility (beta ~0.55). Key stats such as the average daily volume over the past year has been around 1.92 million shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Cytokinetics, Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert I. Blum, the company employs approximately 498 people and listed since April 30, 2004. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 -3.97%, SMA50 -2.17%, SMA200 23.3%). The stock’s 14-day RSI is 43.71 (neutral), while the ATR of 2.9 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -11.76% below its high and over 113.68% above its low. Average 10-day trading volume of 2.20 million shares is slightly above the 3-month average of 1.86 million, indicating heightened recent market interest.

Valuation Metrics

Cytokinetics, Incorporated trades at a P/E ratio of -9.56, slightly below the S&P 500 average, with a price-to-sales ratio of 85.39 and a price-to-book ratio of -11.37 indicating negative book value, which may reflect financial stress. The P/FCF stands at -14.06, also below market averages.

Dividend & Fair Value

Cytokinetics, Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$13.41. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Cytokinetics, Incorporated generated EPS of -$6.53 over the past year. Five-year average earnings growth is -27.07%. Wall Street analysts project EPS growth of 26.31% annually over the next five years. The latest quarter delivered EPS of -$2.55. The next quarter is forecast at -$1.64. Next year's EPS is expected at $8.00. Analyst sentiment is bullish. Analyst rating data shows there are 17 Strong Buy ratings, 17 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $136.00 to $41.00. The high target offers 121.39% upside. The low target suggests -33.26% downside. The mean target is $86.11. This offers 40.18% upside. Cytokinetics, Incorporated earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 60.38%. The prior quarter beat by -16.42%. Over the last six quarters, Apple has recorded several small beats. These include 28.43% in August 08, 2024.

Shareholding & Insider Activity

Cytokinetics, Incorporated has 119.66 million shares outstanding. The public float is 119.10 million shares, elevated short interest at 15.07% of float. This equals 13.83 million shares. The short ratio is 8.42 days. Institutional investors hold 118.77% of the float. Insiders own 0.69%. Blum Robert I holds 358.11 thousand shares, Cragg David has 138.70 thousand shares and Malik Fady Ibraham has 138.55 thousand shares. Over the past six months, insider transactions show net selling. They sold 224.98 thousand shares across 31 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Cytokinetics generated $7.53M in revenue, or $0.08 per share. Gross margin was -57.93%, operating margin -6589.71%, and net profit margin -6988.63%. Returns are negative, with ROA at -63.84% and ROE at 136.22%.
On valuation metrics, Cytokinetics trades at a P/E of -9.56, P/S of 85.39 and P/B of -11.37. The current ratio is 4.53 and quick ratio is 4.53. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -367.82 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -1.95, supported by a cash flow-to-debt ratio of -0.40.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Cytokinetics posted revenue of $7.53M, down slightly from $94.59M in the prior quarter. Gross profit was - $4.36M (margin -57.93%). Operating income was - $496.21M (margin -6589.7%). Net income was- $526.24M (EPS - $5.45).
The company ended the quarter with $615.20M in cash and short-term investments, a total debt of $755.77M, and net debt of $642.37M. Total assets were $824.32M, with equity of - $386.32M. Financials further reflected weakness, with operating cash flow of - $414.33M, free cash flow of - $415.75M, and capital expenditures of - $1.42M.

Price Forecast & Outlook

Our AI price prediction model suggests that Cytokinetics, Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.21%, with price expected at $64.63 by March 13, 2026, within a range of $62.89 to $66.33 3-Month Outlook: Projected fall of -20.63%, reaching $48.76 by May 28, 2026, with a range of $46.89 to $50.83. 1-Year Outlook: Projected gain of 6.12%, with price at $65.19 by February 26, 2027, within a range of $59.28 to $70.89.

Key Takeaways

Cytokinetics, Incorporated (NASDAQ:CYTK) shares are flat 0.38% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cytokinetics, Incorporated trading at a premium to the broader market with a P/E of -9.56. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $77.00, suggesting 25.35% upside. Our AI forecast model points to short-term strength (5.21% over two weeks), a medium-term fall (-20.63% over three months), and a longer-term gain (6.12% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Cytokinetics, Incorporated (CYTK) stock price?

Cytokinetics, Incorporated (NASDAQ: CYTK) stock price is $61.43 in the last trading session. During the trading session, CYTK stock reached the peak price of $62.54 while $60.45 was the lowest point it dropped to. The percentage change in CYTK stock occurred in the recent session was -1.27% while the dollar amount for the price change in CYTK stock was - $0.79.

CYTK's industry and sector of operation?

The NASDAQ listed CYTK is part of Biotechnology industry that operates in the broader Healthcare sector. Cytokinetics, Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CYTK?

Mr. Jeff Lotz
Vice President of Sales & Operations
Mr. Scott R. Jordan
Senior Vice President of Global Marketing & Commercial Strategy
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.
Executive Vice President of R&D
Dr. James A. Spudich Ph.D.
Co-Founder & Member of Scientific Advisory Board
Mr. Robert C. Wong
Vice President & Chief Accounting Officer
Mr. Robert I. Blum
Chief Executive Officer, Pres & Director
Mr. Ching W. Jaw
Senior Vice President & Chief Financial Officer
Mr. Andrew M. Callos
Executive Vice President & Chief Commercial Officer
Ms. Kari K. Loeser J.D.
Vice President & Chief Compliance Officer
Ms. Joanna Siegall
Associate Director of Corporation Communications & Investor Relations
Mr. Steven M. Cook
Senior Vice President of Supply Chain Operations & Technical Operations
Ms. Diane Weiser
Senior Vice President of Corporation Communications & Investor Relations

How CYTK did perform over past 52-week?

CYTK's closing price is 109.59% higher than its 52-week low of $29.31 where as its distance from 52-week high of $70.98 is -13.45%.

How many employees does CYTK have?

Number of CYTK employees currently stands at 498.

Link for CYTK official website?

Official Website of CYTK is: https://www.cytokinetics.com

How do I contact CYTK?

CYTK could be contacted at phone 650 624 3000 and can also be accessed through its website. CYTK operates from 350 Oyster Point Boulevard, South San Francisco, CA 94080, United States.

How many shares of CYTK are traded daily?

CYTK stock volume for the day was 1.45M shares. The average number of CYTK shares traded daily for last 3 months was 1.92M.

What is the market cap of CYTK currently?

The market value of CYTK currently stands at $7.51B with its latest stock price at $61.43 and 122.26M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	498
Beta	0.55
Sales or Revenue	$7.53M
5Y Sales Change%	-0.865%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CYTK Company Profile and Key Details

Cytokinetics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways